




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Letter to the editor

# Continuous positive airway pressure helmet in patients with ARDS due to COVID-19 pneumonia: Insights about a therapy-monitoring protocol



## To the Editor

We have read with great interest the study by Privitera et al.<sup>1</sup> about the use of helmet for continuous positive airway pressure in patients with respiratory failure due to COVID-19 pneumonia. This study is clear in its structure, but we consider that some aspects should be clarified.

First, breathing pattern and respiratory rate seem to be the key guiding element for the adjustment and decision-making along with oxygen saturation.<sup>2,3</sup> However, in our opinion, there are other factors that could interfere with respiratory rate (fever, anxiety, discomfort, or pain). It is obviously a very sensitive factor, but not very specific, especially in an emergency department setting.<sup>3</sup>

Authors did not analyse patients' compliance and comfort regarding the helmet interface, and though it has been said that 11 patients (21.1% of the total) received morphine, the reason is not explained.

Then, the subgroup of helmet failure population and causes of Helmet failure as an interface are not well defined.

On this line, these two aspects could be key remarks for a proper helmet interface evaluation<sup>4</sup> and could provide prevention tools from failure.

Second, at the time of this study, little data on thromboembolic complications from COVID-19 and use of low-molecular-weight heparin were already available in literature. We wondered if this therapy was used by the authors at that time and their results.<sup>5</sup>

This study confirms the excellent results observed with this type of interface in patients with COVID-19, when a strict protocol of use is applied, highlighting the benefits of a correct monitoring.

**Conflict of interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

- [1] Privitera D, Capsoni N, Mazzone A, Airoidi C, Angaroni L, Pierotti, et al. Nursing evaluation during treatment with helmet continuous positive airway pressure in patients with respiratory failure due to COVID-19 pneumonia: a case series. *Aust Crit Care* 2022;35:46–51. <https://doi.org/10.1016/j.aucc.2021.10.001>.
- [2] Brambilla AM, Aliberti S, Prina E, Nicoli F, Del Forno M, Nava S, et al. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. *Intensive Care Med* 2014 Jul;40(7):942–9. <https://doi.org/10.1007/s00134-014-3325-5>. Epub 2014 May 10.
- [3] Tobert DG, Simon PM, Stroetz RW, Hubmayr RD. The determinants of respiratory rate during mechanical ventilation. *Am J Respir Crit Care Med* 1997 Feb;155(2):485–92. <https://doi.org/10.1164/ajrccm.155.2.9032183>.
- [4] Liu Q, Gao Y, Chen R, Cheng Z Noninvasive ventilation with helmet versus control strategy in patients with acute respiratory failure: a systematic review and meta-analysis of controlled studies. *Crit Care* 2016 Aug 23;20(1):265. <https://doi.org/10.1186/s13054-016-1449-4>.
- [5] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemostasis* 2020;18:1094–9. <https://doi.org/10.1111/jth.14817>.

Mariano Mazza, MD\*, Domenica Di Costanzo, MD  
 UOC Pneumologia Semintensiva COVID, A.O. Sant'Anna e San  
 Sebastiano, di Rilievo Nazionale e alta Specializzazione, Via  
 Ferdinando Palasciano, 81100, Caserta, Italy  
 E-mail address: [domenica.dicostanzo@libero.it](mailto:domenica.dicostanzo@libero.it) (D. Di Costanzo).  
 Antonio M. Esquinas, MD, PhD, FCCP, International Fellow AARC,  
 Fellow NIV  
 Intensive Care Unit, Hospital Morales Mesenguer, Murcia, Spain  
 E-mail address: [antmesquinas@gmail.com](mailto:antmesquinas@gmail.com).

\* Corresponding author.

E-mail address: [dottmmazza@gmail.com](mailto:dottmmazza@gmail.com) (M. Mazza).

3 March 2022